Aliskiren: an oral direct renin inhibitor for the treatment of hypertension (Q37377943)

20 August 2017

1 reference

title

Aliskiren: an oral direct renin inhibitor for the treatment of hypertension (English)

1 reference

20 August 2017

main subject

arterial hypertension

0 references

author name string

Cynthia A Sanoski

series ordinal

1

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 February 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

29

1 reference

20 August 2017

issue

2

1 reference

20 August 2017

page(s)

193-212

1 reference

Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Global burden of hypertension: analysis of worldwide data

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Pr

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Angiotensin II receptor antagonists: role in hypertension, cardiovascular disease, and renoprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Angiotensin II receptor blockers in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

The clinical use of angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Bradykinin and the pathophysiology of angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Therapeutic potential of renin inhibitors in the management of cardiovascular disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

The (pro)renin receptor: a new addition to the renin-angiotensin system?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Prorenin and its ancient receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Aliskiren: a renin inhibitor offering a new approach for the treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Structure-based design of aliskiren, a novel orally effective renin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

21 January 2018

Oral renin inhibitors

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Direct Renin inhibition with aliskiren in obese patients with arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Letter by Testa et al regarding article, "Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization".

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Nonallergic angioedema: role of bradykinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Major congenital malformations after first-trimester exposure to ACE inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.2.193

21 January 2018

Identifiers

DOI

10.1592/PHCO.29.2.193

1 reference

20 August 2017

1 reference